Meritage Group’s Nephros NEPH Stock Holding History

Meritage Group’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$643K	Buy	+173,407	New	+$692K	0.02%	13

Other funds holding NEPH

Massachusetts Institute of Technology Cambridge, Massachusetts $695M AUM 43.77% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Bard Associates Chicago, Illinois $431M AUM 30.93% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Meritage Group's NEPH Position: Q3 2026 in Review

Meritage Group opened a new position in Nephros (NEPH) in Q3 2026: 173,407 shares worth $643K. The stake represents 0.02% of the portfolio and ranks #13 among its holdings.

26 funds tracked by Wall St. Rank hold NEPH as of Q3 2026.

Meritage Group held 173,407 shares of Nephros worth $643K as of Q3 2026.
Nephros was a new Meritage Group position in Q3 2026.
Nephros made up 0.02% of Meritage Group's portfolio in Q3 2026, its #13 holding.
26 funds tracked by Wall St. Rank held Nephros as of Q3 2026.

Based on Meritage Group's 13F filing for Q3 2026, filed 13 Nov 2026.